Analyst Ratings January 23, 2026

KBW Elevates Live Oak Bancshares Price Target to $146 Following Robust Q4 Performance

Strong quarterly earnings surpass expectations, prompting optimistic outlook despite anticipated margin normalization

By Priya Menon LOB
KBW Elevates Live Oak Bancshares Price Target to $146 Following Robust Q4 Performance
LOB

Keefe, Bruyette & Woods has increased its price target for Live Oak Bancshares to $146 from $132 and maintained an Outperform rating after the bank's fourth-quarter results exceeded analyst estimates. The bank showcased stronger-than-expected earnings and revenue growth while maintaining stable credit performance. However, KBW anticipates a reversal in strong net interest margin gains as Federal Reserve rate reductions affect its floating rate loan portfolio.

Key Points

  • KBW raised Live Oak Bancshares’ price target to $146, reflecting confidence in the bank’s robust Q4 earnings performance.
  • Live Oak Bancshares reported Q4 earnings per share of $0.95, exceeding estimates by 66.67%, and revenue of $172.91 million, surpassing forecasts by over 14%.
  • The bank’s credit quality remained stable during the quarter, alleviating concerns about the SBA credit cycle.
  • The strong net interest margin experienced in Q4 is expected to decline in the next quarter due to anticipated Federal Reserve rate cuts impacting floating rate loans.

Keefe, Bruyette & Woods (KBW) raised its price target for Live Oak Bancshares (NYSE: LOB) to $146.00 from $132.00 on Friday, while affirming an Outperform rating following the release of the bank’s fourth-quarter earnings report. This move follows a positive market response, with Live Oak Bancshares shares advancing approximately 5% during Thursday’s session, attributable to quarterly results surpassing KBW’s already above-consensus forecasts.

The company’s recent stock performance underscores this momentum, having appreciated 8.4% over the preceding week and delivering an impressive 26.2% return over the previous six months. KBW observed that reported gains could have been even more pronounced if Live Oak had not opted to defer certain Small Business Administration (SBA) loan sales to future periods, which influenced the gain-on-sale fees recognized during the quarter.

For the twelve months ending with this quarter, Live Oak Bancshares posted diluted earnings per share of $2.23. Nonetheless, analysis by InvestingPro suggests the stock price currently exceeds its estimated Fair Value. Notably, KBW highlighted steady credit performance during the quarter, addressing stakeholder apprehensions regarding the SBA credit cycle’s stability.

Although KBW retained most earnings and revenue projections for upcoming periods, the firm indicated an expectation that the robust net interest margin observed in the fourth quarter is likely to moderate in the subsequent quarter. This anticipated change correlates with Federal Reserve rate cuts that will impact the company’s floating rate loan portfolio.

Additional financial details from Live Oak’s fourth-quarter 2025 report revealed earnings per share of $0.95, substantially outperforming the consensus estimate of $0.57 – representing a 66.67% earnings surprise. The quarter's revenue totaled $172.91 million, surpassing estimates by 14.27%. These figures collectively reflect a strong operational performance and highlight critical information for investors evaluating the bank’s financial health.

While these developments have attracted the attention of analysts and investors, it is important to consider the cyclical factors and projected interest rate environment that may influence Live Oak Bancshares’ future financial results and stock valuation.

Risks

  • Potential decline in net interest margins as Federal Reserve rate cuts affect Live Oak’s floating rate loan portfolio, which may impact future earnings.
  • Delayed sale of SBA loans could influence gain-on-sale fees, affecting quarterly earnings volatility.
  • Despite strong recent performance, the stock may be trading above its calculated Fair Value, posing valuation risk to investors.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026